Skip to Content

SANDOZ 625 (Rivastigmine Tartrate 6 mg)

Pill with imprint SANDOZ 625 is Orange / Red, Capsule-shape and has been identified as Rivastigmine Tartrate 6 mg. It is supplied by Sandoz Pharmaceuticals Inc..

Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 6 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for SANDOZ 625

Rivastigmine tartrate 6 mg SANDOZ 625
Rivastigmine tartrate 6 mg SANDOZ 625
Rivastigmine tartrate 6 mg SANDOZ 625

Rivastigmine Tartrate

Imprint
SANDOZ 625
Strength
6 mg
Color
Orange / Red
Size
18.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Cholinesterase inhibitors
Pregnancy Category
B - No proven risk in humans
CSA Schedule
Not a controlled drug
Labeler / Supplier
Sandoz Pharmaceuticals Inc.
National Drug Code (NDC)
00781-2617
Inactive Ingredients
gelatin, hypromelloses, magnesium stearate, microcrystalline cellulose, ferric oxide red, silicon dioxide, titanium dioxide, ferric oxide yellow

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.